Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer

Yi An Cheng; Tung Ho Wu; Yun Ming Wang; Tian Lu Cheng; I. Ju Chen; Yun Chi Lu; Kuo Hsiang Chuang; Chih Kuang Wang; Chiao Yun Chen; Rui An Lin; Huei Jen Chen; Tzu Yi Liao; En Shuo Liu; Fang Ming Chen

doi:10.1186/s12951-020-00680-9

Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer

Yi An Cheng, Tung Ho Wu, Yun Ming Wang, Tian Lu Cheng, I. Ju Chen, Yun Chi Lu, Kuo Hsiang Chuang, Chih Kuang Wang, Chiao Yun Chen, Rui An Lin, Huei Jen Chen, Tzu Yi Liao, En Shuo Liu, Fang Ming Chen

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Background: Developing a universal strategy to improve the specificity and sensitivity of PEGylated nanoaparticles (PEG-NPs) for assisting in the diagnosis of tumors is important in multimodality imaging. Here, we developed the anti-methoxypolyethylene glycol (mPEG) bispecific antibody (BsAb; mPEG × HER2), which has dual specificity for mPEG and human epidermal growth factor receptor 2 (HER2), with a diverse array of PEG-NPs to confer nanoparticles with HER2 specificity and stronger intensity. Result: We used a one-step formulation to rapidly modify the nanoprobes with mPEG × HER2 and optimized the modified ratio of BsAbs on several PEG-NPs (Lipo-DiR, SPIO, Qdot and AuNP). The αHER2/PEG-NPs could specifically target MCF7/HER2 cells (HER2++) but not MCF7/neo1 cells (HER2+/-). The αHER2/Lipo-DiR and αHER2/SPIO could enhance the sensitivity of untargeted PEG-NPs on MCF7/HER2 (HER2++). In in vivo imaging, αHER2/Lipo-DiR and αHER2/SPIO increased the specific targeting and enhanced PEG-NPs accumulation at 175% and 187% on 24 h, respectively, in HER2-overexpressing tumors. Conclusion: mPEG × HER2, therefore, provided a simple one-step formulation to confer HER2-specific targeting and enhanced sensitivity and contrast intensity on HER2 positive tumors for multimodality imaging. [Figure not available: see fulltext.]

Original language	English
Article number	118
Pages (from-to)	118
Journal	Journal of Nanobiotechnology
Volume	18
Issue number	1
DOIs	https://doi.org/10.1186/s12951-020-00680-9
Publication status	Published - Aug 27 2020

Keywords

Anti-PEG antibody
Bispecific antibody
Cancer image
Contrast agent
Multimodality image
One-step formulation
PEGylated nanoparticle
Polyethylene glycol
Tumor specificity

ASJC Scopus subject areas

Bioengineering
Medicine (miscellaneous)
Molecular Medicine
Biomedical Engineering
Applied Microbiology and Biotechnology
Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12951-020-00680-9

Cite this

Cheng, Y. A., Wu, T. H., Wang, Y. M., Cheng, T. L., Chen, I. J., Lu, Y. C., Chuang, K. H., Wang, C. K., Chen, C. Y., Lin, R. A., Chen, H. J., Liao, T. Y., Liu, E. S., & Chen, F. M. (2020). Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer. Journal of Nanobiotechnology, 18(1), 118. Article 118. https://doi.org/10.1186/s12951-020-00680-9

Cheng, YA, Wu, TH, Wang, YM, Cheng, TL, Chen, IJ, Lu, YC, Chuang, KH, Wang, CK, Chen, CY, Lin, RA, Chen, HJ, Liao, TY, Liu, ES & Chen, FM 2020, 'Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer', Journal of Nanobiotechnology, vol. 18, no. 1, 118, pp. 118. https://doi.org/10.1186/s12951-020-00680-9

@article{fe5d078bcb4248ef9b1d834ab1601743,

title = "Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer",

abstract = "Background: Developing a universal strategy to improve the specificity and sensitivity of PEGylated nanoaparticles (PEG-NPs) for assisting in the diagnosis of tumors is important in multimodality imaging. Here, we developed the anti-methoxypolyethylene glycol (mPEG) bispecific antibody (BsAb; mPEG × HER2), which has dual specificity for mPEG and human epidermal growth factor receptor 2 (HER2), with a diverse array of PEG-NPs to confer nanoparticles with HER2 specificity and stronger intensity. Result: We used a one-step formulation to rapidly modify the nanoprobes with mPEG × HER2 and optimized the modified ratio of BsAbs on several PEG-NPs (Lipo-DiR, SPIO, Qdot and AuNP). The αHER2/PEG-NPs could specifically target MCF7/HER2 cells (HER2++) but not MCF7/neo1 cells (HER2+/-). The αHER2/Lipo-DiR and αHER2/SPIO could enhance the sensitivity of untargeted PEG-NPs on MCF7/HER2 (HER2++). In in vivo imaging, αHER2/Lipo-DiR and αHER2/SPIO increased the specific targeting and enhanced PEG-NPs accumulation at 175% and 187% on 24 h, respectively, in HER2-overexpressing tumors. Conclusion: mPEG × HER2, therefore, provided a simple one-step formulation to confer HER2-specific targeting and enhanced sensitivity and contrast intensity on HER2 positive tumors for multimodality imaging. [Figure not available: see fulltext.] ",

keywords = "Anti-PEG antibody, Bispecific antibody, Cancer image, Contrast agent, Multimodality image, One-step formulation, PEGylated nanoparticle, Polyethylene glycol, Tumor specificity",

author = "Cheng, {Yi An} and Wu, {Tung Ho} and Wang, {Yun Ming} and Cheng, {Tian Lu} and Chen, {I. Ju} and Lu, {Yun Chi} and Chuang, {Kuo Hsiang} and Wang, {Chih Kuang} and Chen, {Chiao Yun} and Lin, {Rui An} and Chen, {Huei Jen} and Liao, {Tzu Yi} and Liu, {En Shuo} and Chen, {Fang Ming}",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s).",

year = "2020",

month = aug,

day = "27",

doi = "10.1186/s12951-020-00680-9",

language = "English",

volume = "18",

pages = "118",

journal = "Journal of Nanobiotechnology",

issn = "1477-3155",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer

AU - Cheng, Yi An

AU - Wu, Tung Ho

AU - Wang, Yun Ming

AU - Cheng, Tian Lu

AU - Chen, I. Ju

AU - Lu, Yun Chi

AU - Chuang, Kuo Hsiang

AU - Wang, Chih Kuang

AU - Chen, Chiao Yun

AU - Lin, Rui An

AU - Chen, Huei Jen

AU - Liao, Tzu Yi

AU - Liu, En Shuo

AU - Chen, Fang Ming

PY - 2020/8/27

Y1 - 2020/8/27

N2 - Background: Developing a universal strategy to improve the specificity and sensitivity of PEGylated nanoaparticles (PEG-NPs) for assisting in the diagnosis of tumors is important in multimodality imaging. Here, we developed the anti-methoxypolyethylene glycol (mPEG) bispecific antibody (BsAb; mPEG × HER2), which has dual specificity for mPEG and human epidermal growth factor receptor 2 (HER2), with a diverse array of PEG-NPs to confer nanoparticles with HER2 specificity and stronger intensity. Result: We used a one-step formulation to rapidly modify the nanoprobes with mPEG × HER2 and optimized the modified ratio of BsAbs on several PEG-NPs (Lipo-DiR, SPIO, Qdot and AuNP). The αHER2/PEG-NPs could specifically target MCF7/HER2 cells (HER2++) but not MCF7/neo1 cells (HER2+/-). The αHER2/Lipo-DiR and αHER2/SPIO could enhance the sensitivity of untargeted PEG-NPs on MCF7/HER2 (HER2++). In in vivo imaging, αHER2/Lipo-DiR and αHER2/SPIO increased the specific targeting and enhanced PEG-NPs accumulation at 175% and 187% on 24 h, respectively, in HER2-overexpressing tumors. Conclusion: mPEG × HER2, therefore, provided a simple one-step formulation to confer HER2-specific targeting and enhanced sensitivity and contrast intensity on HER2 positive tumors for multimodality imaging. [Figure not available: see fulltext.]

AB - Background: Developing a universal strategy to improve the specificity and sensitivity of PEGylated nanoaparticles (PEG-NPs) for assisting in the diagnosis of tumors is important in multimodality imaging. Here, we developed the anti-methoxypolyethylene glycol (mPEG) bispecific antibody (BsAb; mPEG × HER2), which has dual specificity for mPEG and human epidermal growth factor receptor 2 (HER2), with a diverse array of PEG-NPs to confer nanoparticles with HER2 specificity and stronger intensity. Result: We used a one-step formulation to rapidly modify the nanoprobes with mPEG × HER2 and optimized the modified ratio of BsAbs on several PEG-NPs (Lipo-DiR, SPIO, Qdot and AuNP). The αHER2/PEG-NPs could specifically target MCF7/HER2 cells (HER2++) but not MCF7/neo1 cells (HER2+/-). The αHER2/Lipo-DiR and αHER2/SPIO could enhance the sensitivity of untargeted PEG-NPs on MCF7/HER2 (HER2++). In in vivo imaging, αHER2/Lipo-DiR and αHER2/SPIO increased the specific targeting and enhanced PEG-NPs accumulation at 175% and 187% on 24 h, respectively, in HER2-overexpressing tumors. Conclusion: mPEG × HER2, therefore, provided a simple one-step formulation to confer HER2-specific targeting and enhanced sensitivity and contrast intensity on HER2 positive tumors for multimodality imaging. [Figure not available: see fulltext.]

KW - Anti-PEG antibody

KW - Bispecific antibody

KW - Cancer image

KW - Contrast agent

KW - Multimodality image

KW - One-step formulation

KW - PEGylated nanoparticle

KW - Polyethylene glycol

KW - Tumor specificity

UR - http://www.scopus.com/inward/record.url?scp=85090008343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090008343&partnerID=8YFLogxK

U2 - 10.1186/s12951-020-00680-9

DO - 10.1186/s12951-020-00680-9

M3 - Article

C2 - 32854720

AN - SCOPUS:85090008343

SN - 1477-3155

VL - 18

SP - 118

JO - Journal of Nanobiotechnology

JF - Journal of Nanobiotechnology

IS - 1

M1 - 118

ER -

Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Additional file 1 of Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer